This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

53/100

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Introduction Drugs that prevent the onset, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed. Methods We searched ClinicalTrials.gov for all current Phase 1, 2 and 3 clinical trials for AD and mild cognitive impairment (MCI) attributed to AD. We created an automated computational database platform to search, archive, organize, and analyze the derived data. The Common Alzheimer's Disease Research Ontology (CADRO) was used to identify treatment targets and drug mechanisms. Results On the index date of January 1, 2023, there were 187 trials assessing 141 unique treatments for AD. Phase 3 included 36 agents in 55 trials; 87 agents were in 99 Phase 2 trials; and Phase 1 had 31 agents in 33 trials. Disease-modifying therapies were the most common drugs comprising 79% of drugs in trials. Twenty-eight percent of candidate therapies are repurposed agents. Populating all current Phase 1, 2, and 3 trials will require 57,465 participants. Discussion The AD drug development pipeline is advancing agents directed at a variety of target processes. Highlights There are currently 187 trials assessing 141 drugs for the treatment of Alzheimer's disease (AD).Drugs in the AD pipeline address a variety of pathological processes.More than 57,000 participants will be required to populate all currently registered trials.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2023). Alzheimer's disease drug development pipeline: 2023. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1002/trc2.12385

Vancouver

Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2023. Alzheimer's & dementia (New York, N. Y.). 2023. doi:10.1002/trc2.12385. PMID: 37251912.

BibTeX

@article{cummings2023-37251912,
  author  = {Cummings, J. and Zhou, Y. and Lee, G. and Zhong, K. and Fonseca, J. and Cheng, F.},
  title   = {{Alzheimer's disease drug development pipeline: 2023}},
  journal = {Alzheimer's \& dementia (New York, N. Y.)},
  year    = {2023},
  doi     = {10.1002/trc2.12385},
  pmid    = {37251912},
  url     = {https://doi.org/10.1002/trc2.12385}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Results On the index date of January 1, 2023, there were 187 trials assessing 141 unique treatments for AD.

Why it matters

This report found that as of January 1, 2023, there were 187 trials assessing 141 unique treatments for Alzheimer's disease, with disease-modifying therapies the most common. It describes the current drug development pipeline and the number of participants needed, but reports no results on whether any treatment works.

Study details

Study designclinical trial
Participants36
Evidence strengthLow

How this study scored 53/100

Published in a leading specialty journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here and still being cited, so those were left out: it earned 38 of the 72 points we could judge it on, which is 53 out of 100.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (Alzheimer's & dementia (New York, N. Y.))
Journal's citation record	1 / 4	Alzheimer s & Dementia Translational Research & Clinical Interventions: journal h-index 84 (OpenAlex, 2026-10-29)
Study design	0 / 12	Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	3 / 5	2023 — within 6 year(s) of the newest study here
Sample size	1 / 4	36 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	— / 7	Citation count not trusted: 3 of 25 library studies citing it were published more than a year before it - a sign OpenAlex merged several works under this DOI — left out of this score
Citations per year	— / 5	Citation count not trusted (see above) — left out of this score
Impact for its field and year	— / 6	Citation count not trusted (see above) — left out of this score
Cited by studies here	— / 6	Library citations not trusted (see above) — left out of this score
Still being cited	— / 4	Citation count not trusted (see above) — left out of this score
Senior author's track record	3 / 4	Last-listed author Feixiong Cheng: h-index 94 (OpenAlex, whole career)
Institution's track record	1 / 3	Case Western Reserve University: institution h-index 1,159 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 37251912)
Free to read	2 / 2	Free to read
Points	38 / 72	Scored on 15 of 20 parts. We have no data for the rest, so they are left out: 38 of the 72 points we could judge it on is 53 out of 100.
Total	53 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

25 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Mild cognitive impairment

Also in Mild cognitive impairment

76 studies in the library are filed under Mild cognitive impairment with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Mild cognitive impairment hub.

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →